Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/12255
Title: Cost-Effectiveness of Proton Versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient VolumeeBased Analysis
Authors: Fernandes, Ricardo Ribeiro Alves
Vianna, Cid Manso de Mello
Guerra, Renata Leborato
Cancela, Marianna de Camargo
Almeida, Liz Maria de
Pereira, Adail José da Conceição
Viegas, Celia Maria Pais
Ferman, Sima Esther
Corrêa, Flavia de
Keywords: Análise Custo-Benefício
Cost-Benefit Analysis
Avaliação da Tecnologia Biomédica
Technology Assessment Biomedical
Pediatria
Pediatrics
Meduloblastoma
Medulloblastoma
Terapia com Prótons
Proton Therapy
Necessidades e Demandas de Serviços de Saúde
Health Services Needs and Demand
Terapêutica
Therapeutics
Issue Date: Dec-2019
Publisher: Value in Health Regional
Abstract: Proton radiation therapy offers advantages over photon therapy, assisting with severe side effect avoidance. Pedi atric patients with medulloblastoma have demonstrated benefit from this technology in recently published cohort studies. Objectives: To compare the costs and benefits between proton and photon therapy in treating pediatric medulloblastoma. Methods: The model was built with a lifetime horizon from the Brazilian health system perspective using a 3% discount rate. A micro simulation model was developed after a literature search, comparing scenarios of equipment life span and number of patients treated per year (50, 100, and 150 patients with 10, 25, and 20 years of equipment life span). The baseline parameters were 50 patients treated annually and 20 years of equipment life span. Results: The quality-adjusted life-year gain was 2.71, and the average incre mental cost-effectiveness ratio was $34 590.54 per quality-adjusted life-year. For the willingness-to-pay threshold of 1 gross domestic product per capita, it was observed that the incorporation of the technology would be cost-effective if more than 150 patients were treated per year. The weight of the equipment life span and other variables was limited when it varied in the sensitivity analysis, without significant changes to the model results. Conclusions: Proton therapy is not cost-effective for pediatric medulloblastoma treatment from the Brazilian health system perspective. The in vestment is not worth when considering the number of potential patients and the country dimensions.
URI: https://ninho.inca.gov.br/jspui/handle/123456789/12255
ISSN: 2212-1102
Appears in Collections:Artigos de Periódicos da área de Pesquisa Populacional



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.